Celcuity
NASDAQ: CELCMinneapolis, US · Founded 2011 · Delaware corporation · 257 employees on LinkedIn · 2 known investors
Celcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
Founders & leadership
Celcuity was founded in 2011 by Lance G. Laing and Brian F. Sullivan.
Board
DF
RE
Richard E. BullerBoard director
LT
Leo T. FurchtBoard director
PA
Polly A. MurphyBoard director
RJ
Richard J. NigonBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$303M disclosed across 9 rounds · 2014–2023
▶$130MraisedSep 2025 · 2 investors · BiotechnologyRule 506(b)
▶$130MraisedSep 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vicky HahneExecutive Officer
- David F. DalveyDirector
- Richard E. BullerDirector
- Polly A. MurphyDirector
- Richard J. NigonDirector
- Leo T. FurchtDirector
- Lance G. LaingExecutive Officer, Director
- Brian F. SullivanExecutive Officer, Director, Promoter
- Offering amount
- $352.7M
- Amount sold
- $130M
- Sales commissions
- $4.3M
- Placement agents
- LCT Capital, LLC
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedOct 2024 · 2 investors · BiotechnologyRule 506(b)
▶$50MraisedOct 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lance G. LaingExecutive Officer, Director, Promoter
- David F. DalveyDirector
- Vicky HahneExecutive Officer
- Richard E. BullerDirector
- Leo T. FurchtDirector
- Brian F. SullivanExecutive Officer, Director, Promoter
- Polly A. MurphyDirector
- Richard J. NigonDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedNov 2023 · 38 investors · BiotechnologyRule 506(b)
▶$2.6MraisedNov 2023 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard J. NigonDirector
- Vicky HahneExecutive Officer
- Polly A. MurphyDirector
- Richard E. BullerDirector
- Brian F. SullivanExecutive Officer, Director
- David F. DalveyDirector
- Leo FurchtDirector
- Lance G. LaingExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2.6M
- Sales commissions
- $258K
- Placement agents
- Cedar Point Capital, LLC
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.9MraisedNov 2023 · 39 investors · BiotechnologyRule 506(b)
▶$5.9MraisedNov 2023 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vicky HahneExecutive Officer
- David F. DalveyDirector
- Leo FurchtDirector
- Polly A. MurphyDirector
- Richard E. BullerDirector
- Richard J. NigonDirector
- Brian F. SullivanExecutive Officer, Director
- Lance G. LaingExecutive Officer, Director
- Offering amount
- $6.6M
- Amount sold
- $5.9M
- Sales commissions
- $560K
- Placement agents
- Cedar Point Capital, LLC
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100MraisedMay 2022 · 11 investors · BiotechnologyRule 506(b)
▶$100MraisedMay 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard J. NigonDirector
- Brian F. SullivanExecutive Officer, Director
- Richard E. BullerDirector
- Leo T. FurchtDirector
- Vicky HahneExecutive Officer
- David F. DalveyDirector
- Lance G. LaingExecutive Officer, Director
- Offering amount
- $156M
- Amount sold
- $100M
- Sales commissions
- $4M
- Placement agents
- Jefferies LLC
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedApr 2021 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David F. DalveyDirector
- Lance G. LaingExecutive Officer, Director, Promoter
- Brian F. SullivanExecutive Officer, Director, Promoter
- Richard J. NigonDirector
- Vicky HahneExecutive Officer
- Richard E. BullerDirector
- Leo T. FurchtDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$325KraisedFeb 2016 · 6 investors · BiotechnologyRule 506(b)
▶$325KraisedFeb 2016 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lance G. LaingExecutive Officer, Director, Promoter
- David F. DalveyDirector
- Brian F. SullivanExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $325K
- Sales commissions
- $300K
- Placement agents
- Cedar Point Capital, LLC
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Minnesota, 2011
- Federal exemptions
- 06b
▶$5.2MraisedFeb 2016 · 40 investors · BiotechnologyRule 506(b)
▶$5.2MraisedFeb 2016 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian F. SullivanExecutive Officer, Director, Promoter
- Lance G. LaingExecutive Officer, Director, Promoter
- David F. DalveyDirector
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- Sales commissions
- $510K
- Proceeds to insiders
- $175K
- Placement agents
- Cedar Point Capital, LLC
- First sale
- Dec 2015
- Incorporated
- Limited Liability Company, Minnesota, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapKite Pharma33 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Exelixis24 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Dialectic Therapeutics24 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Celularity22 shared keywordsCelularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Companies competing with Celcuity for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Celcuity do?
- Celcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
- Who founded Celcuity?
- Celcuity was founded by Lance G. Laing, Brian F. Sullivan in 2011.
- Who are Celcuity's investors?
- Celcuity's investors include Brightstone Venture Capital, New Enterprise Associates (NEA).
- How much funding has Celcuity raised?
- Celcuity has disclosed $303M raised across 9 rounds.
- Where is Celcuity headquartered?
- Celcuity is headquartered in Minneapolis, US.